Cytek Biosciences (CTKB) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.03
- Estimate
- -$0.02
- Surprise
- -55.0%
- Revenue (period 2026-06-30)
- $48.1M
- Score today
- 5.2/10
Revenue source: xbrl.
How the report landed
Cytek Biosciences (CTKB) reported adjusted EPS of -$0.03, in line with the -$0.02 estimate.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CTKB Sell at 5.2/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate; this quarter's -55.0% surprise compares with a -548.2% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Target reached (-14.6% upside)
- Quality below floor (3.6 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.14
- Stop
- $5.71
Risk check: RSI 76 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
CTKB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $798.1M
- P/E (fwd)
- 87.7
- 52-week range
- $3.31–$6.32
- Off 52-week high
- 2.8%
- RSI (14)
- 76
- Volume vs avg
- 1.17×
- Score today
- 5.2/10